Revista Médica del Uruguay
versão impressa ISSN 0303-3295
OLIVER, Carolina et al. Trasplante autólogo de progenitores hematopoyéticos en pacientes con mieloma múltiple: análisis de factores pronósticos y sobrevida. Experiencia del Hospital Británico. Rev. Méd. Urug. [online]. 2011, vol.27, n.4, pp. 202-210. ISSN 0303-3295.
Summary Introduction: autologic transplant of hematopoietic progenitors is regarded as the standard in the first line treatment of patients with multiple myeloma (MM) younger than 65 years old. Objective: to analyse global survival and incident free survival in patients with multiple myeloma transplanted at the British Hospital. Method: we conducted a retrospective study of patients who received the first autologic transplant of hematopoietic progenitors. Results: 56 autologic transplants of hematopoietic progenitors were performed from July 1, 1999 through June 30, 2010 in 48 patients with MM. Upon analysis of patients after the first transplant, 46% were women and 54% were men. Median age was 54 years old (32-65 years old). 73% were IgG, 17% were IgA and 10% were light chains.60.4% achieved CR/nCR (CR), non- confirmed CR and VGPR) after transplant. With an average follow-up of 58.6 months (5.84-186.56), the median global survival was 121.8 months (IC 95%: 70.1-173.54 months). No significant differences were found in the global survival in patients who achieved CR/nCR after autologic transplant of hematopoietic progenitors and those who failed to achieve it (log Rank p=0.162. The median incident-free survival was 56 months (IC 95%: 42.2-70.4 months). Conclusions: autologic transplant of hematopoietic progenitors is an essential tool to treat patients with MM and it is a safe procedure at the Hematology Unit of the British Hospital.
Palavras-chave : HEMATOPOIETIC STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; MULTIPLE MYELOMA.